Payment overview · 2025
General Payments
$1,438.89
86 reported records · 22 companies
Healthcare provider profile · identity verified
Manhal Naoumi, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · WARREN, MI · NPI 1689643124
Verified facts
What the public records show
CMS Open Payments records show Manhal Naoumi, M.D. received $1,438.89 in general payments during 2025 across 86 reported records.
Amgen Inc. accounted for 20.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 34 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Linzess, Mounjaro, Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Linzess by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 175 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 175 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 86 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 104 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 303 claims for Eliquis by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LANTUS as an associated drug or biological on 12 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Lantus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $290.11 | 20.2% | 20 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $279.88 | 19.4% | 20 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $157.95 | 11.0% | 9 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $91.54 | 6.4% | 5 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $79.02 | 5.5% | 4 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $65.75 | 4.6% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $60.96 | 4.2% | 4 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $56.10 | 3.9% | 3 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $49.84 | 3.5% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $39.30 | 2.7% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $36.62 | 2.5% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $31.70 | 2.2% | 2 | 2025 |
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $28.98 | 2.0% | 1 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $25.05 | 1.7% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $24.98 | 1.7% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $21.23 | 1.5% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $20.56 | 1.4% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $17.90 | 1.2% | 1 | 2025 |
| Ethicon Inc. | Unresolved — no canonical attribution shown | $17.68 | 1.2% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $15.45 | 1.1% | 1 | 2025 |
| Insmed, Inc. | Unresolved — no canonical attribution shown | $14.31 | 1.0% | 1 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $13.98 | 1.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,438.89 | 86 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $223.02 | 16 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $223.02 | 16 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $203.43 | 16 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $161.92 | 13 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $109.78 | 7 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $79.02 | 4 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $76.45 | 4 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $65.75 | 3 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $56.10 | 3 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $54.14 | 3 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $51.21 | 3 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $49.84 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $39.30 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $37.40 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $36.62 | 2 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $34.00 | 2 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $31.70 | 2 | 2025 |
Source payment records
|
|||||
| ARISTADA Normalized: aristada |
Drug | Alkermes, Inc. | $28.98 | 1 | 2025 |
Source payment records
|
|||||
| LYBALVI Normalized: lybalvi |
Drug | Alkermes, Inc. | $28.98 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $26.96 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $26.96 | 2 | 2025 |
Source payment records
|
|||||
| SPINRAZA Normalized: spinraza |
Biological | Biogen, Inc. | $25.05 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $24.98 | 1 | 2025 |
Source payment records
|
|||||
| JASCAYD Normalized: jascayd |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $22.70 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $21.23 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $20.73 | 1 | 2025 |
Source payment records
|
|||||
| General - Pain Management Normalized: general pain management |
Device | Boston Scientific Corporation | $20.56 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $17.90 | 1 | 2025 |
Source payment records
|
|||||
| Monarch Platform Normalized: monarch platform |
Device | Ethicon Inc. | $17.68 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $16.67 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $15.88 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $15.45 | 1 | 2025 |
Source payment records
|
|||||
| Arikayce Normalized: arikayce |
Drug | Insmed, Inc. | $14.31 | 1 | 2025 |
Source payment records
|
|||||
| KOSELUGO Normalized: koselugo |
Drug | Alexion Pharmaceuticals, Inc. | $13.98 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 303 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 175 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 61 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 35 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 104 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
61 | 17 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
175 | 61 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
175 | 61 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
86 | 18 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
43 | 14 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
104 | 25 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
303 | 83 |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | LANTUS open payments reported associated product |
CMS Open Payments — General Payments 12 supporting records · 11 recipient NPIs · example record 1233196856 |
Lantus · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 899 | 258 |
| Amlodipine Besylate | Amlodipine Besylate | 731 | 183 |
| Losartan Potassium | Losartan Potassium | 718 | 184 |
| Metformin Hcl | Metformin Hcl | 605 | 122 |
| Omeprazole | Omeprazole | 603 | 168 |
| Metoprolol Succinate | Metoprolol Succinate | 405 | 118 |
| Levothyroxine Sodium | Levothyroxine Sodium | 358 | 80 |
| Eliquis | Apixaban | 303 | 83 |
| Simvastatin | Simvastatin | 284 | 50 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 277 | 107 |
| Hydrochlorothiazide | Hydrochlorothiazide | 272 | 71 |
| Lisinopril | Lisinopril | 272 | 75 |
| Prednisone | Prednisone | 268 | 176 |
| Furosemide | Furosemide | 253 | 80 |
| Diclofenac Sodium | Diclofenac Sodium | 249 | 81 |
| Fluticasone Propionate | Fluticasone Propionate | 246 | 87 |
| Montelukast Sodium | Montelukast Sodium | 239 | 61 |
| Alendronate Sodium | Alendronate Sodium | 233 | 54 |
| Metoprolol Tartrate | Metoprolol Tartrate | 193 | 63 |
| Jardiance | Empagliflozin | 175 | 61 |
| Potassium Chloride | Potassium Chloride | 173 | 60 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 171 | 43 |
| Allopurinol | Allopurinol | 167 | 43 |
| Clopidogrel | Clopidogrel Bisulfate | 163 | 60 |
| Carvedilol | Carvedilol | 162 | 56 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 156 | 46 |
| Famotidine | Famotidine | 149 | 58 |
| Pantoprazole Sodium | Pantoprazole Sodium | 149 | 57 |
| Hydralazine Hcl | Hydralazine Hcl | 145 | 49 |
| Fenofibrate | Fenofibrate Nanocrystallized | 136 | 34 |
| Gabapentin | Gabapentin | 126 | 36 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 124 | 40 |
| Meclizine Hcl | Meclizine Hcl | 120 | 33 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 106 | 54 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 105 | 83 |
| Tamsulosin Hcl | Tamsulosin Hcl | 105 | 30 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 104 | 35 |
| Januvia | Sitagliptin Phosphate | 104 | 22 |
| Ozempic | Semaglutide | 104 | 25 |
| Glimepiride | Glimepiride | 103 | 26 |
| Atenolol | Atenolol | 99 | 21 |
| Meloxicam | Meloxicam | 92 | 18 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 87 | 77 |
| Trulicity | Dulaglutide | 86 | 18 |
| Hydrocortisone | Hydrocortisone | 84 | 30 |
| Pravastatin Sodium | Pravastatin Sodium | 84 | 26 |
| Nitroglycerin | Nitroglycerin | 77 | 27 |
| Methocarbamol | Methocarbamol | 74 | 44 |
| Pregabalin | Pregabalin | 73 | 17 |
| Trazodone Hcl | Trazodone Hcl | 70 | 17 |
| Metformin Hcl Er | Metformin Hcl | 69 | 17 |
| Xarelto | Rivaroxaban | 67 | 15 |
| Cephalexin | Cephalexin | 65 | 54 |
| Donepezil Hcl | Donepezil Hcl | 65 | 15 |
| Ibuprofen | Ibuprofen | 65 | 40 |
| Zolpidem Tartrate | Zolpidem Tartrate | 65 | 25 |
| Cefuroxime | Cefuroxime Axetil | 64 | 56 |
| Breo Ellipta | Fluticasone/Vilanterol | 62 | 14 |
| Amiodarone Hcl | Amiodarone Hcl | 61 | 22 |
| Farxiga | Dapagliflozin Propanediol | 61 | 14 |
| Linzess | Linaclotide | 61 | 17 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 59 | 18 |
| Ketoconazole | Ketoconazole | 59 | 18 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 59 | 24 |
| Vascepa | Icosapent Ethyl | 59 | suppressed |
| Glipizide | Glipizide | 57 | 11 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 57 | suppressed |
| Alprazolam | Alprazolam | 54 | 17 |
| Amoxicillin | Amoxicillin | 54 | 46 |
| Bupropion Xl | Bupropion Hcl | 54 | 17 |
| Nifedipine Er | Nifedipine | 54 | 19 |
| Fenofibrate | Fenofibrate | 52 | 14 |
| Bumetanide | Bumetanide | 51 | 14 |
| Spironolactone | Spironolactone | 51 | 19 |
| Dicyclomine Hcl | Dicyclomine Hcl | 49 | 22 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 47 | 16 |
| Entresto | Sacubitril/Valsartan | 43 | 14 |
| Mupirocin | Mupirocin | 42 | 27 |
| Duloxetine Hcl | Duloxetine Hcl | 40 | 16 |
| Flecainide Acetate | Flecainide Acetate | 40 | suppressed |
| Temazepam | Temazepam | 40 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 40 | 16 |
| Azithromycin | Azithromycin | 39 | 35 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 38 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 37 | 15 |
| Escitalopram Oxalate | Escitalopram Oxalate | 37 | 11 |
| Colchicine | Colchicine | 36 | 11 |
| Finasteride | Finasteride | 36 | 15 |
| Glipizide Er | Glipizide | 36 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 36 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 36 | 17 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 35 | 17 |
| Mounjaro | Tirzepatide | 35 | suppressed |
| Alcohol Swab | Alcohol Antiseptic Pads | 34 | 14 |
| Letrozole | Letrozole | 33 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 32 | suppressed |
| Tradjenta | Linagliptin | 32 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 32 | suppressed |
| Ezetimibe | Ezetimibe | 29 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 29 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 28 | 18 |
| Buspirone Hcl | Buspirone Hcl | 27 | 13 |
| Calcitriol | Calcitriol | 27 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 27 | 12 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 27 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 26 | suppressed |
| Levetiracetam | Levetiracetam | 26 | 11 |
| Metronidazole | Metronidazole | 26 | 23 |
| Gemfibrozil | Gemfibrozil | 25 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 25 | suppressed |
| Latanoprost | Latanoprost | 23 | suppressed |
| Ondansetron Odt | Ondansetron | 23 | 12 |
| Ranolazine Er | Ranolazine | 23 | 11 |
| Tacrolimus | Tacrolimus | 23 | suppressed |
| Fluconazole | Fluconazole | 22 | 15 |
| Klor-Con M20 | Potassium Chloride | 22 | 12 |
| Memantine Hcl | Memantine Hcl | 22 | suppressed |
| Methimazole | Methimazole | 22 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 21 | suppressed |
| Novolog Flexpen | Insulin Aspart | 21 | suppressed |
| Aripiprazole | Aripiprazole | 20 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 20 | suppressed |
| Lubiprostone | Lubiprostone | 20 | suppressed |
| Repatha Sureclick | Evolocumab | 20 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 20 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 19 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 19 | suppressed |
| Mirtazapine | Mirtazapine | 19 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 19 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 18 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 18 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 18 | suppressed |
| Baclofen | Baclofen | 17 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 17 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 17 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 17 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 16 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 16 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 16 | 13 |
| Labetalol Hcl | Labetalol Hcl | 16 | suppressed |
| Sotalol | Sotalol Hcl | 16 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 15 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 15 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 15 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 15 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 14 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 14 | suppressed |
| Diazepam | Diazepam | 14 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 14 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 14 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Acyclovir | Acyclovir | 13 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 13 | suppressed |
| Digoxin | Digoxin | 13 | suppressed |
| Fluocinonide | Fluocinonide | 13 | suppressed |
| Humalog | Insulin Lispro | 13 | suppressed |
| Nystatin | Nystatin | 13 | 12 |
| Dilt-Xr | Diltiazem Hcl | 12 | suppressed |
| Loperamide | Loperamide Hcl | 12 | 11 |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 12 | suppressed |
| Naproxen | Naproxen | 12 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 12 | suppressed |
| Chlorthalidone | Chlorthalidone | 11 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 11 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 11 | suppressed |
| Lovastatin | Lovastatin | 11 | suppressed |
| Multaq | Dronedarone Hcl | 11 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 11 | suppressed |
| Sucralfate | Sucralfate | 11 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,438.89 · 86 records | Amgen Inc. | ARISTADA, Arikayce, Cologuard Collection Kit, Dexcom G6 Transmitter, ELIQUIS, EVENITY, FREESTYLE LIBRE 3, General - Pain Management, JARDIANCE, JASCAYD, KISUNLA, KOSELUGO, KRYSTEXXA, LEQVIO, LINZESS, LYBALVI, MOUNJARO, Monarch Platform, NURTEC ODT, OTEZLA, Ohtuvayre, Ozempic, PAXLOVID, REPATHA, REXULTI, Rybelsus, SPINRAZA, TRELEGY ELLIPTA, TZIELD, VOQUEZNA, Wegovy, XIFAXAN, ZAVZPRET, ZEPBOUND | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error